Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of three active pharmaceutical ingredients: alendronate, fluticasone, and salmeterol. Alendronate is a bisphosphonate used primarily to treat and prevent osteoporosis by inhibiting osteoclast-mediated bone resorption. Fluticasone is an inhaled corticosteroid that reduces inflammation in the airways, commonly used for asthma and chronic obstructive pulmonary disease (COPD). Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle to improve airflow in conditions like asthma and COPD. While fixed-dose combinations of fluticasone and salmeterol are widely available for respiratory diseases, there are no known approved or marketed products combining all three agents—alendronate with fluticasone and salmeterol—in a single formulation. Each component has distinct mechanisms of action targeting different therapeutic areas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alendronate + fluticasone + salmeterol.